Freya Pharma Solutions Names Christa van Kan Director of Clinical Ops

Freya Pharma Solutions, a late clinical stage company focusing on the development of pharmaceutical therapies for women diagnosed with Female Sexual Disorders (FSD), appointed Christa van Kan, director of clinical operations. 

Van Kan brings more than 25 years of clinical operations and trial management experience to Freya Pharma Solutions.

“Christa possesses more than 25 years of experience in the contract research organization (CRO) industry,” said Marcel Wijma, CEO, Freya Pharma Solutions. “As our newly appointed director clinical operations, she will be responsible for driving the confirmatory clinical development of our FSD therapy platform. During her impressive career, Christa has led numerous clinical programs from ‘first-in-human’ to Phase 3, managing performance targets to meet company goals, maintain resources, and coordinate process development to ensure optimal trial outcomes.”

Wijma added: “We are delighted that Christa is joining Freya’s senior team as we prepare to initiate our confirmatory clinical trial, investigating Lybrido, an ‘on demand’ therapy for the treatment of premenopausal women suffering from Female Sexual Interest/Arousal Disorder (FSIAD).”

Van Kan was most recently Interim Director Clinical Operations at Healx, a Cambridge (UK) based AI drug discovery company, overseeing all clinical projects performed by the company and training and coaching the clinical team members. Prior to Healx, Ms. van Kan was co-founder in 1998 and Director Clinical Operations of PSR Group, a Dutch CRO. Ms. van Kan holds an MSc degree in Biomedical Sciences from the State University Leiden in The Netherlands.

“I am excited to join Freya at a pivotal time for the company as we plan to soon advance Lybrido into a confirmatory clinical trial for the treatment of FSIAD,” said van Kan. “I look forward to working with Freya’s leadership and R&D team as we seek to transform the lives of women living with this severe sexual disorder by developing novel treatments that open new pathways to target lack of sexual interest and desire, with the overarching goal of improving their sexual health.”

Freya Pharma Solutions is currently preparing the clinical development program with several studies with Lybrido in Europe, to be followed later by trials in the U.S.

In September 2022, Freya received early scientific advice from the European Medicines Agency (EMA) on its upcoming confirmatory ALETTA clinical trial, providing constructive and valuable elements that will contribute to the successful development of the therapy.

The company is confident that it is well on track with the clinical development of Lybrido as a treatment for women suffering from sexual dysfunction.